Dey I, Sprivulis P Emergency physicians can reliably assess emergency department patient cardiac output using the USCOM continuous wave Doppler cardiac output monitor. Emerg Med Australas. 2005 Jun;17(3):193-9.
Diercks DB, Peacock WF, Kirk JD, Weber JE ED patients with heart failure: identification of an observational unit-appropriate cohort. Am J Emerg Med. 2006 May;24(3):319-24.
Kass DA, Maughan WL, Guo ZM, Kono A, Sunagawa K, Sagawa K Comparative influence of load versus inotropic states on indexes of ventricular contractility: experimental and theoretical analysis based on pressure-volume relationships. Circulation. 1987 Dec;76(6):1422-36. Erratum in: Circulation 1988 Mar;77(3):559.
Kirkpatrick JN, Vannan MA, Narula J, Lang RM Echocardiography in heart failure: applications, utility, and new horizons. J Am Coll Cardiol. 2007 Jul 31;50(5):381-96. Epub 2007 Jul 13. Review.
Lam LL, Cameron PA, Schneider HG, Abramson MJ, Müller C, Krum H Meta-analysis: effect of B-type natriuretic peptide testing on clinical outcomes in patients with acute dyspnea in the emergency setting. Ann Intern Med. 2010 Dec 7;153(11):728-35. doi: 10.7326/0003-4819-153-11-201012070-00006.
McMurray JJ, Stewart S Epidemiology, aetiology, and prognosis of heart failure. Heart. 2000 May;83(5):596-602. Review.
Mendez GF, Cowie MR The epidemiological features of heart failure in developing countries: a review of the literature. Int J Cardiol. 2001 Sep-Oct;80(2-3):213-9. Review.
Patel N, Dodsworth M, Mills JF Cardiac output measurement in newborn infants using the ultrasonic cardiac output monitor: an assessment of agreement with conventional echocardiography, repeatability and new user experience. Arch Dis Child Fetal Neonatal Ed. 2011 May;96(3):F206-11. doi: 10.1136/adc.2009.170704. Epub 2010 Jul 6.
Peacock WF Acute Emergency Department management of heart failure. Heart Fail Rev. 2003 Oct;8(4):335-8. Review.
Peacock WF Heart failure management in the emergency department observation unit. Prog Cardiovasc Dis. 2004 Mar-Apr;46(5):465-85. Review.
Peacock WF Using the emergency department clinical decision unit for acute decompensated heart failure. Cardiol Clin. 2005 Nov;23(4):569-88, viii. Review.
Sanderson JE, Chan SK, Chan WW, Hung YT, Woo KS The aetiology of heart failure in the Chinese population of Hong Kong--a prospective study of 730 consecutive patients. Int J Cardiol. 1995 Aug;51(1):29-35.
Sanderson JE, Tse TF Heart failure: a global disease requiring a global response. Heart. 2003 Jun;89(6):585-6.
Silver MA, Peacock WF 4th, Diercks DB Optimizing treatment and outcomes in acute heart failure: beyond initial triage. Congest Heart Fail. 2006 May-Jun;12(3):137-45. Review.
Smith BE, Madigan VM Non-invasive method for rapid bedside estimation of inotropy: theory and preliminary clinical validation. Br J Anaesth. 2013 Oct;111(4):580-8. doi: 10.1093/bja/aet118. Epub 2013 May 3.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.